الفهرس 
EpidemiologyOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
ndometrial cancer is the most common female genital
cancer in the developing world, with adenocarcinoma of
the endometrium the most common type (De Haydu et al.,
2015).
In our study we reviewed of medical records on 104
patients including demographic data and clinic-pathological
factors were reported, including age, performance status
(ECOG), comorbidities, risk factors, surgery, adjuvant
treatment, metastatic treatment, treatment response and survival
rates were collected.
The exact cause of endometrial cancer is unknown. An
increased level of estrogen may play a role. Estrogen helps
stimulate the buildup of the lining of the uterus (Boggess et al.,
2013).
Our population under study had: median age of the studied
population was 61 years (range: 45-77), majority of our patients
(86.5%) had good ECOG performance status (1), (57.6%) of the
patients were presented to us with stage I disease, most common
symptoms at presentation was abnormal vaginal bleeding in
(96.15%) and the most common pathological subtype was
endometrioid adenocarcinoma (88.4%).
As regard adjuvant treatment fifty patients (66.7% of
total patients received adjuvant treatment) received Rth on whole pelvis till 50 Gy. Radiotherapy improved the OS and
DFS. The meta-analysis and Cochrane Review also found a
trend to improve survival with the addition of radiation in
patients with at least 2 risk factors (age, lymphovascular space
involvement) including grade 3 and stage IC disease (Kong et
al., 2007).
In our study, twenty five patients (33.3%) received
adjuvant Cth, twenty three patients received Taxol/Carb with
statistically significant improvement in OS. It is safe and
efficient to use Taxol/Carb as first line of treatment in patients
with advanced endometrial cancer with overall response rates
ranging from 40% to 63% (Nomura et al., 2011).
Thirteen patients received Taxol/Carb as first line of
treatment in metastatic patients with statistically improvement
in OS and PFS. The median progression free survival was 15
months and the median overall survival was 25 months in
metastatic endometrial cancer patients who received
Taxol/Carb for 6-9 cycles (Pectasides et al., 2008).